secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-104144
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports FY2025 net loss $19.4M; GBM trial shows 97% PFS improvement
--------------------------------------------------------------------------

- Net loss $19.4M ($4.44/share) vs $30.4M ($17.05/share) prior year; cash $27.1M vs $11.1M year-end 2024.
- Updated GBM data: mPFS 13.0 months for DRI patients vs 6.6 months SOC (+97%); mOS not yet reached at 17.2+ months.
- Closed initial $20.1M of $40.2M private placement; net proceeds $18.5M extend cash runway into H1 2027.
- Kate Rochlin promoted to President and COO in February 2026.
- Anticipates FDA guidance on regulatory pathway for GBM program by H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312526104144/0001193125-26-104144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312526104144/inab-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-104144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer